Left ventricular hypertrophy in hypertension is a common complication modified by cardiovascular risk factors, comorbidities, and the renin-angiotensin-aldosterone system.
This review highlights the evolving epidemiology and pathophysiology of left ventricular hypertrophy in hypertensive patients, emphasizing the role of comorbidities and molecular mechanisms.
INTRODUCTION: Left ventricular hypertrophy (LVH) is a common complication to hypertension, indicating the presence of hypertensive heart disease, which puts the patient at a very high risk for subsequent clinical cardiovascular events like sudden cardiac death, stroke, myocardial infarction and heart failure. AREAS COVERED: The epidemiology of LVH has changed in recent years as a consequence of the development of new diagnostic tools and demographic changes in hypertensive populations. Expert commentary: In individual hypertensive patients, the presence and type of LVH and associated systolic and diastolic myocardial dysfunction is modified by the co-presence of other cardiovascular risk factors and comorbidities and as well as activation of the reninangiotensin-aldosterone system and other molecular mechanisms involved in LVH pathophysiology. The purpose of this review is to give a clinical update on LVH in hypertension.
Cramariuc et al. (Mon,) conducted a review in Left ventricular hypertrophy in hypertension. Left ventricular hypertrophy in hypertension is a common complication modified by cardiovascular risk factors, comorbidities, and the renin-angiotensin-aldosterone system.